Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 185

Sort by

Sort Order Select

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

A Rare Presentation of Acute Immune Thrombocytopenia, Refractory to First Line Therapy, Despite Euthyroid State

Emily Molina, DO, MSPH, Gursharon Sanghera, MD, Patrick Hanley, MD, Rafat Ahmed, MD

Blood (2019) 134 (Supplement_1): 4900.

https://doi.org/10.1182/blood-2019-126200

Published: 2019

Journal Articles

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P.M. Verkleij, MD, Monique C. Minnema, Okke de Weerdt, MD, Patricia W.C. Bosman, MSc, Kristine A. Frerichs, MD, Alexandra J. Croockewit, MD PhD, Saskia K. Klein, MD PhD, Gerard Bos, MD PhD, Tuna Mutis, Wouter J. Plattel, MD, Ellen van der Spek, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1879.

https://doi.org/10.1182/blood-2019-124339

Published: 2019

Journal Articles

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World

Marjorie E Zettler, PhD MPH, Chadi Nabhan, MDMBA, FACP, Ajeet Gajra, MD FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 3490.

https://doi.org/10.1182/blood-2019-129553

Published: 2019

Journal Articles

History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes

Michelle A. Roesler, BS, Amy Linabery, PhD MS, Michaela Richardson, MPH, Adina Cioc, MD, Betsy A Hirsch, PhD, Phuong L. Nguyen, MD, Erica D. Warlick, MD, Jenny Poynter, PhD

Blood (2019) 134 (Supplement_1): 3014.

https://doi.org/10.1182/blood-2019-130940

Published: 2019

Journal Articles

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Blood (2019) 134 (Supplement_1): 236.

https://doi.org/10.1182/blood-2019-122406

Published: 2019

Journal Articles

Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study

Xinxin Cao, Jian Li, MD, Ai-lin Zhao, Xue-min Gao, Hua-cong Cai, MD, Lu Zhang, MD, Yan Zhang, MD, Jun Feng, MD, Miao Chen, MD, Tie-nan Zhu, MD, Na Niu, Jian Sun, MD, Zhi-yong Liang, MD, Dao-Bin Zhou, Ming-hui Duan, MD

Blood (2019) 134 (Supplement_1): 294.

https://doi.org/10.1182/blood-2019-122220

Published: 2019

Journal Articles

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie Johnson, MD, Pauline Brice, John Radford, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, MD PhD, Bastian Von Tresckow, Margaret A. Shipp, MD, Alex F. Herrera, MD, Jianxin Lin, Eunhee Kim, Mohammed Farooqui, Patricia Marinello, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 240.

https://doi.org/10.1182/blood-2019-127280

Published: 2019

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

Journal Articles

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

David A. Bond, MD, Vedat Yildiz, Lai Wei, PhD, Lapo Alinari, MD PhD, Basem M. William, MRCP,MD, Jonathan E. Brammer, MD, Beth A. Christian, MD, Kristie A. Blum, MD, Kami J. Maddocks, MD

Blood (2019) 134 (Supplement_1): 4091.

https://doi.org/10.1182/blood-2019-130539

Published: 2019

Journal Articles

Late Effects in Survivors of Infant Acute Lymphoblastic Leukemia from the 3 Consecutive Japanese Nationwide Clinical Trials

Yuki Aoki, Akira Hayakawa, MD PhD, Kazutoshi Koike, MD PhD, Hisamichi Tauchi, MD PhD, Eiichi Ishii, MD PhD, Katsuyoshi Koh, MD, Takako Miyamura, MD PhD, Yasushi Ishida, MD PhD, Akiko Kada, MPH, Akiko M Saito, MD PhD, Atsushi Manabe, MD PhD, Keizo Horibe, MD PhD, Shuki Mizutani, MD PhD, Miho Maeda, MD, Daisuke Tomizawa, MD PhD

Blood (2019) 134 (Supplement_1): 4559.

https://doi.org/10.1182/blood-2019-123881

Published: 2019

Journal Articles

Does Venetoclax Cause Vitiligo?

Sujatha Baddam, MD, Jorge Diaz Castro, MD

Blood (2019) 134 (Supplement_1): 5139.

https://doi.org/10.1182/blood-2019-130854

Published: 2019

Journal Articles

The Clinical, Economic, and Humanistic Burden of Patients with β-Thalassemia: A US-Centric Review of the Literature

Elizabeth S. Mearns, Chuka Udeze, Ronda Copher, Sujit Sheth, MD

Blood (2019) 134 (Supplement_1): 5855.

https://doi.org/10.1182/blood-2019-125676

Published: 2019

Journal Articles

A Global Systematic Literature Review on the Burden of Illness in Transfusion-Dependent β-Thalassemia

Monica Turner, Sohan Deshpande, Madhura Chitnis, Michael Byrnes, Christopher Pelligra, Amy Rines-MacEachern, Jessica Morison, Derek Tang, PhD BSPharm

Blood (2019) 134 (Supplement_1): 5786.

https://doi.org/10.1182/blood-2019-124307

Published: 2019

Journal Articles

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

Blood (2019) 134 (Supplement_1): 1130.

https://doi.org/10.1182/blood-2019-124234

Published: 2019

Journal Articles

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, MD, Robert W. Chen, MD, Hun Ju Lee, MD, Philippe Armand, MD PhD, Nathalie A Johnson, MD PhD, Pauline Brice, MD, John Radford, MD FRCP, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian Von Tresckow, MD, Margaret A. Shipp, MD, Eunhee Kim, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2018) 132 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2018-99-117045

Published: 2018

Journal Articles

Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs)

Catherine Kendall Major, BS, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Nicholas J Short, MD, Naval G. Daver, MD, Elias J. Jabbour, MD, Richard E Champlin, MD, Guillermo Garcia-Manero, MD, Marina Y. Konopleva, MD PhD, Michael Andreeff, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Sherry A. Pierce, BSN, BA, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3976.

https://doi.org/10.1182/blood-2018-99-119892

Published: 2018

Journal Articles

Impact of Myeloablative Total Body Irradiation Versus Chemotherapy on Late Effects and Survival Among Adolescent and Young Adult Survivors of Hematopoietic Cell Transplantation for Acute Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Catherine J. Lee, MD, Soyoung Kim, Heather R. Tecca, Ruta Brazauskas, PhD, Minoo Battiwalla, MD, David K. Buchbinder, MD MSHS, Mary E. D. Flowers, MD, Rachel Phelan, MDMPH, Bronwen E. Shaw, MD PhD, Lori S Muffly, MD

Blood (2018) 132 (Supplement 1): 252.

https://doi.org/10.1182/blood-2018-99-113031

Published: 2018

Journal Articles

Evaluation of Endocrine Complications in Beta-Thalassemia Intermedia Patients: A Cross Sectional Multi-Center Study

Blood (2018) 132 (Supplement 1): 2343.

https://doi.org/10.1182/blood-2018-99-110903

Published: 2018

Journal Articles

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Mateo Mejia Saldarriaga, MD, Amir Steinberg, MD, Adam F. Binder, MD

Blood (2018) 132 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2018-99-112652

Published: 2018

NARROW

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

A Rare Presentation of Acute Immune Thrombocytopenia, Refractory to First Line Therapy, Despite Euthyroid State

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World

History of Autoimmune Disease Is Associated with Increased Risk for Myelodysplastic Syndromes

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma

Late Effects in Survivors of Infant Acute Lymphoblastic Leukemia from the 3 Consecutive Japanese Nationwide Clinical Trials

Does Venetoclax Cause Vitiligo?

The Clinical, Economic, and Humanistic Burden of Patients with β-Thalassemia: A US-Centric Review of the Literature

A Global Systematic Literature Review on the Burden of Illness in Transfusion-Dependent β-Thalassemia

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs)

Impact of Myeloablative Total Body Irradiation Versus Chemotherapy on Late Effects and Survival Among Adolescent and Young Adult Survivors of Hematopoietic Cell Transplantation for Acute Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Evaluation of Endocrine Complications in Beta-Thalassemia Intermedia Patients: A Cross Sectional Multi-Center Study

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only